{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:37:42Z","timestamp":1790753862525,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.coi.2020.03.015","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T06:55:20Z","timestamp":1588229720000},"page":"42-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs"],"prefix":"10.1016","volume":"65","author":[{"given":"Francesco","family":"Berti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Micoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2020.03.015_bib0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.50.4.533","article-title":"Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic of sugar-protein antigens","volume":"50","author":"Avery","year":"1929","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2020.03.015_bib0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.82.6.445","article-title":"Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides","volume":"82","author":"Macleod","year":"1945","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2020.03.015_sbref0015","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1073\/pnas.1717160115","article-title":"Technologies to address antimicrobial resistance","volume":"115","author":"Baker","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.03.015_bib0020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/00006454-198708000-00040","article-title":"Capsular polysaccharide of Haemophilus influenzae type b as a vaccine","volume":"6","author":"Parke","year":"1987","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.coi.2020.03.015_bib0025","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1542\/peds.60.5.730","article-title":"Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland","volume":"60","author":"Peltola","year":"1977","journal-title":"Pediatrics"},{"key":"10.1016\/j.coi.2020.03.015_bib0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2020.03.015_bib0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/iai.34.1.144-146.1981","article-title":"Group C Neisseria meningitidis variant polysaccharide vaccines in children","volume":"34","author":"Steinhoff","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.coi.2020.03.015_bib0040","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0264-410X(92)90091-W","article-title":"Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C","volume":"10","author":"Costantino","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2020.03.015_bib0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1469-0691.2002.00424.x","article-title":"The new pneumococcal vaccine","volume":"8","author":"Obaro","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.coi.2020.03.015_bib0050","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/17460441.2011.609554","article-title":"The design of semi-synthetic and synthetic glycoconjugate vaccines","volume":"6","author":"Costantino","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.coi.2020.03.015_bib0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/femsre\/fuy011","article-title":"Potential targets for next generation anti-microbial glycoconjugate vaccines","volume":"42","author":"Micoli","year":"2018","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.coi.2020.03.015_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061451","article-title":"Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends","volume":"23","author":"Micoli","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.coi.2020.03.015_bib0065","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2020.03.015_bib0070","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.1095209","article-title":"A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b","volume":"305","author":"Verez-Bencomo","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.coi.2020.03.015_bib0075","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/acs.bioconjchem.5b00617","article-title":"A synthetic carbohydrate conjugate vaccine candidate against shigellosis: improved bioconjugation and impact of alum on immunogenicity","volume":"27","author":"van der Put","year":"2016","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.coi.2020.03.015_bib0080","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1016\/j.vaccine.2015.06.102","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized phase I study","volume":"33","author":"Hatz","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2020.03.015_bib0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate caccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coi.2020.03.015_bib0090","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebiom.2017.07.013","article-title":"Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe","volume":"22","author":"Launay","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coi.2020.03.015_bib0095","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3389\/fimmu.2017.01884","article-title":"A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a ahigellosis-endemic country","volume":"8","author":"Obiero","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2020.03.015_bib0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1073\/pnas.1819612116","article-title":"On the mechanisms of conjugate vaccines","volume":"116","author":"Rappuoli","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.03.015_sbref0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4615","article-title":"Glycoconjugate vaccines: principles and mechanisms","volume":"10","author":"Rappuoli","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2020.03.015_bib0110","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/nm.2587","article-title":"A sweet T cell response","volume":"17","author":"Rappuoli","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2020.03.015_sbref0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1073\/pnas.1816401115","article-title":"Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines","volume":"116","author":"Sun","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.03.015_bib0120","first-page":"1","article-title":"Glycoconjugate vaccines: current approaches towards faster vaccine design","author":"Micoli","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2020.03.015_bib0125","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1039\/C4CS00388H","article-title":"Towards the next generation of biomedicines by site-selective conjugation","volume":"45","author":"Hu","year":"2016","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.coi.2020.03.015_bib0130","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.chembiol.2018.07.002","article-title":"Resurrecting the bacterial tyrosyl-tRNA synthetase\/tRNA pair for expanding the genetic code of both E. coli and eukaryotes","volume":"25","author":"Italia","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.coi.2020.03.015_bib0135","doi-asserted-by":"crossref","first-page":"13564","DOI":"10.1073\/pnas.1307228110","article-title":"Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.03.015_sbref0140","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1021\/acs.chemrev.8b00066","article-title":"Toward automated enzymatic synthesis of oligosaccharides","volume":"118","author":"Wen","year":"2018","journal-title":"Chem Rev"},{"key":"10.1016\/j.coi.2020.03.015_bib0145","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1021\/cb400463u","article-title":"Immunoactivity of protein conjugates of carba analogues from Neisseria meningitidis a capsular polysaccharide","volume":"8","author":"Gao","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.coi.2020.03.015_bib0150","unstructured":"https:\/\/vaxxilon.com\/wp-content\/uploads\/2019\/06\/Haemophilus_influenzae_type_B.pdf."},{"key":"10.1016\/j.coi.2020.03.015_sbref0155","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1073\/pnas.1701885114","article-title":"Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide","volume":"114","author":"Carboni","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.03.015_bib0160","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/nnm.11.151","article-title":"Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine","volume":"7","author":"Safari","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.coi.2020.03.015_bib0165","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1126\/science.298.5599.1790","article-title":"N-Linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli","volume":"298","author":"Wacker","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.coi.2020.03.015_sbref0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-019-0110-z","article-title":"Recent advances in the production of recombinant glycoconjugate vaccines","volume":"4","author":"Kay","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.coi.2020.03.015_bib0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/glycob\/cwz031","article-title":"Glycoengineering bioconjugate vaccines, therapeutics, and diagnostics in E. coli","volume":"29","author":"Harding","year":"2019","journal-title":"Glycobiology"},{"key":"10.1016\/j.coi.2020.03.015_sbref0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08869-9","article-title":"A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host","volume":"10","author":"Harding","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2020.03.015_bib0185","doi-asserted-by":"crossref","first-page":"18655","DOI":"10.1073\/pnas.1907833116","article-title":"A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae","volume":"116","author":"Feldman","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.03.015_bib0190","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jit800","article-title":"Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli","volume":"209","author":"Wacker","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2020.03.015_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134478","article-title":"Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB","volume":"10","author":"Gerke","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2020.03.015_bib0200","doi-asserted-by":"crossref","first-page":"24922","DOI":"10.1074\/jbc.M114.566570","article-title":"Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants","volume":"289","author":"Rossi","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2020.03.015_bib0205","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1128\/CVI.00023-16","article-title":"Toll-like receptor activation by generalized modules for membrane antigens from Lipid A mutants of Salmonella enterica serovars Typhimurium and Enteritidis","volume":"23","author":"Rossi","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coi.2020.03.015_bib0210","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02379-17","article-title":"IgG responses to porins and lipopolysaccharide within an outer membrane-based vaccine against nontyphoidal Salmonella develop at discordant rates","volume":"9","author":"Schager","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.coi.2020.03.015_bib0215","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.vaccine.2016.11.089","article-title":"Characterization of O-antigen delivered by generalized modules for membrane antigens (GMMA) vaccine candidates against nontyphoidal Salmonella","volume":"35","author":"De Benedetto","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2020.03.015_bib0220","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1073\/pnas.1807655115","article-title":"Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella","volume":"41","author":"Micoli","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.03.015_bib0225","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201800376","article-title":"Emerging technologies for low-cost, rapid vaccine manufacture","volume":"14","author":"Kis","year":"2019","journal-title":"Biotechnol J"},{"key":"10.1016\/j.coi.2020.03.015_bib0230","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.biotechadv.2017.05.003","article-title":"Bioengineering bacterial outer membrane vesicles as vaccine platform","volume":"35","author":"Gerritzen","year":"2017","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.coi.2020.03.015_bib0235","doi-asserted-by":"crossref","first-page":"E3609","DOI":"10.1073\/pnas.1518311113","article-title":"Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies","volume":"113","author":"Chen","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.03.015_bib0240","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/bs.mie.2017.06.032","article-title":"Glycoengineered outer membrane vesicles as a platform for vaccine development","volume":"597","author":"Valguarnera","year":"2017","journal-title":"Meth Enzymol"},{"key":"10.1016\/j.coi.2020.03.015_bib0245","doi-asserted-by":"crossref","first-page":"E3106","DOI":"10.1073\/pnas.1718341115","article-title":"Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies","volume":"115","author":"Stevenson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791520300388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791520300388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:35:35Z","timestamp":1760603735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791520300388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":49,"alternative-id":["S0952791520300388"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2020.03.015","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2020.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}